SCIENCE@home

Molecular mechanisms underlying cyclophosphamide-induced ovarian injury and protective strategies

Ehab E. Sharata,Taha Bakry,Habiba Gamal Atta,Habiba Atef Mohammed,Nazema Shaker Diab,Rofaida Ashraf Atef,Roaa Sayed Hosney,M. Omar,Ramadan A. M. Hemeida

Published 2025 in Naunyn-Schmiedeberg's Archives of Pharmacology

ABSTRACT

Cyclophosphamide (CP) is an anti-cancer medication that also treats chronic inflammatory illnesses caused by the immune system. Although CP is widely used, it can occasionally have limited therapeutic efficacy due to its significant combined toxicities. Ovarian damage caused by CP is a major problem for patients, and premature ovarian failure (POF) is a serious side effect of CP that commonly affects female patients. Mechanistic investigations have implicated oxidative stress, inflammatory responses, and apoptosis as critical components in the etiology of CP-induced POF, although the exact process by which this ovarian toxicity occurs remains unclear. After CP causes ovarian cells to generate proinflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), nuclear factor kappa B (NF-κB) is activated. The activation of the NLRP3 inflammasome is the subsequent stage. In addition, Nrf2/HO-1 has been identified as an important signaling pathway that mitigates oxidative stress in CP-induced POF due to its anti-inflammatory and antioxidative characteristics. Moreover, several recent studies highlighted the role of α-klotho deficiency in ovarian aging. Quercetin, resveratrol, berberine, curcumin, irbesartan, mirtazapine, sildenafil, atorvastatin, donepezil, cilostazol, moxibustion, LCZ696, buspirone, levomilnacipran, melatonin, diosmin, and azilsartan are some of the agents that may protect against ovarian injury caused by CP, as shown in Graphical abstract. Our goal in writing this study is to provide a concise overview of the possible redox molecular pathways that cause ovarian harm in CP and how to potentially ameliorate them. Finally, investigation into these molecular pathways may pave the way for early ovarian damage relief and for the development of different agent strategies to alleviate CP-mediated POF. Schematic illustration summarizing the molecular mechanisms underlying cyclophosphamide-induced ovarian injury and the protective strategies of various pharmacological and natural agents. The illustration demonstrates how the specified agents provide their protective effects by targeting critical pathogenic pathways associated with cyclophosphamide-induced ovarian damage Schematic illustration summarizing the molecular mechanisms underlying cyclophosphamide-induced ovarian injury and the protective strategies of various pharmacological and natural agents. The illustration demonstrates how the specified agents provide their protective effects by targeting critical pathogenic pathways associated with cyclophosphamide-induced ovarian damage

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-100 of 339 references · Page 1 of 4

1234
Next

CITED BY

Showing 1-5 of 5 citing papers · Page 1 of 1